Pfizer Receives FDA Fast Track Designation for Duchenne Muscular Dystrophy Investigational Gene Therapy Pharmaceutical Investing
Merck to Hold Third-Quarter 2020 Sales and Earnings Conference Call on October 27 Pharmaceutical Investing
Public coverage of AbbVie's SKYRIZI® for the treatment of Moderate to Severe Plaque Psoriasis is now available across additional jurisdictions Biotech Investing
Gilead Sciences Presents Data From HIV Research and Development Programs at HIV Glasgow 2020 Biotech Investing
CStone, Pfizer Enter into Strategic Collaboration to Address Oncological Needs in China Pharmaceutical Investing
Algernon Announces Enrollment of 100 Patients in Multinational 2b/3 Human Study of Ifenprodil for Treatment of COVID-19 Biotech Investing
Health Canada Approves REBLOZYL® , New Class of Treatment for Adult Patients Living with Beta Thalassemia Biotech Investing
U.S. FDA Approves Pfizer's XELJANZ® for the Treatment of Active Polyarticular Course Juvenile Idiopathic Arthritis Pharmaceutical Investing
Abbott's FreeStyle® Libre 3 System Receives CE Mark - Features World's Smallest, Thinnest Sensor with Best-in-Class Performance at the Same Low Cost for People with Diabetes Medical Device Investing
AbbVie Receives Orphan Drug and Fast Track Designations from the U.S. Food and Drug Administration for Elezanumab, an Investigational Monoclonal Antibody RGMa Inhibitor, for the Treatment of Spinal Cord Injury Biotech Investing
